期刊
JOURNAL OF IMMUNOTHERAPY
卷 40, 期 3, 页码 94-103出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CJI.0000000000000157
关键词
antiangiogenesis; NKG2D; fusion protein; scFv-MICA; antibodies
资金
- National Natural Science Foundation of China [NSFC81072561, NSFC81102364, NSFC81273425]
- The Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University) [JKGP201101]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Graduate Student Innovation Project - Huahai Pharmaceutical Co. [CX13S-009HH]
A single-chain variable fragment (scFv) targeting vascular endothelial growth factor receptor 2 was previously generated from a phage display library in our laboratory. However, it has shortened half-life and lacks Fc fragment for effector cell recognition. To address these challenges, a ligand of NK-cell receptor NKG2D was fused to the scFv and created a fusion protein scFvmajor histocompatibility complex class I-related chain A (MICA), which is expected to recognize tumor cells through the scFv moiety and stimulate NK cells through the MICA. The fusion protein demonstrated specific binding to both vascular endothelial growth factor receptor 2 and NKG2D in protein-based and cell-based assays. In addition, it demonstrated antiangiogenic activities including restraining the proliferation, migration, transwell invasion, and tube formation of human umbilical vein endothelial cells. Furthermore, the fusion protein exhibited significant cytotoxicity on K562, MDA-MB-435, and B16F10 cells and triggered NK92 cell-mediated cytotoxicity on MDA-MB-435 cells by stimulating the release of significant cytokines. The fusion protein targeting strategy, therefore, provides a means to engage lymphocyte effector cells against tumor specific antigen overexpressing tumor cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据